Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1974 1
1977 1
1980 1
1981 5
1982 6
1983 9
1984 7
1985 2
1986 3
1987 4
1988 12
1989 14
1990 12
1991 11
1992 10
1993 6
1994 10
1995 7
1996 16
1997 8
1998 14
1999 14
2000 11
2001 7
2002 9
2003 8
2004 7
2005 12
2006 9
2007 8
2008 9
2009 11
2010 5
2011 11
2012 13
2013 11
2014 6
2015 6
2016 9
2017 17
2018 7
2019 8
2020 13
2021 13
2022 11
2023 5
2024 13
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

388 results

Results by year

Filters applied: . Clear all
Page 1
Applications of single-cell and bulk RNA sequencing in onco-immunology.
Kuksin M, Morel D, Aglave M, Danlos FX, Marabelle A, Zinovyev A, Gautheret D, Verlingue L. Kuksin M, et al. Among authors: morel d. Eur J Cancer. 2021 May;149:193-210. doi: 10.1016/j.ejca.2021.03.005. Epub 2021 Apr 15. Eur J Cancer. 2021. PMID: 33866228 Free article. Review.
Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients.
Chen J, Levy A, Tian AL, Huang X, Cai G, Fidelle M, Rauber C, Ly P, Pizzato E, Sitterle L, Piccinno G, Liu P, Durand S, Mao M, Zhao L, Iebba V, Felchle H, Mallard de La Varende AL, Fischer JC, Thomas S, Greten TF, Jones JC, Monge C, Demaria S, Formenti S, Belluomini L, Dionisi V, Massard C, Blanchard P, Robert C, Quevrin C, Lopes E, Clémenson C, Mondini M, Meziani L, Zhan Y, Zeng C, Cai Q, Morel D, Sun R, Laurent PA, Mangoni M, Di Cataldo V, Arilli C, Trommer M, Wegen S, Neppl S, Riechelmann RP, Camandaroba MP, Neto ES, Fournier PE, Segata N, Holicek P, Galluzzi L, Buqué A, Alves Costa Silva C, Derosa L, Kroemer G, Chen C, Zitvogel L, Deutsch E. Chen J, et al. Among authors: morel d. Cancer Cell. 2025 Mar 10;43(3):361-379.e10. doi: 10.1016/j.ccell.2025.02.010. Cancer Cell. 2025. PMID: 40068595 Free article.
Expanding the phenotype of ASXL3-related syndrome: A comprehensive description of 45 unpublished individuals with inherited and de novo pathogenic variants in ASXL3.
Schirwani S, Albaba S, Carere DA, Guillen Sacoto MJ, Milan Zamora F, Si Y, Rabin R, Pappas J, Renaud DL, Hauser N, Reid E, Blanchet P, Foulds N, Dixit A, Fisher R, Armstrong R, Isidor B, Cogne B, Schrier Vergano S, Demirdas S, Dykzeul N, Cohen JS, Grand K, Morel D, Slavotinek A, Albassam HF, Naik S, Dean J, Ragge N, Costa C, Tedesco MG, Harrison RE, Bouman A, Palen E, Challman TD, Willemsen MH, Vogt J, Cunniff C, Bergstrom K, Walia JS, Bruel AL, Kini U, Alkuraya FS, Slegesky V, Meeks N, Girotto P, Johnson D; DDD Study; Newbury-Ecob R, Ockeloen CW, Prontera P, Lynch SA, Li D, Graham JM Jr, Pierson TM, Balasubramanian M. Schirwani S, et al. Among authors: morel d. Am J Med Genet A. 2021 Nov;185(11):3446-3458. doi: 10.1002/ajmg.a.62465. Epub 2021 Aug 26. Am J Med Genet A. 2021. PMID: 34436830 Free article.
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Chabanon RM, Morel D, Eychenne T, Colmet-Daage L, Bajrami I, Dorvault N, Garrido M, Meisenberg C, Lamb A, Ngo C, Hopkins SR, Roumeliotis TI, Jouny S, Hénon C, Kawai-Kawachi A, Astier C, Konde A, Del Nery E, Massard C, Pettitt SJ, Margueron R, Choudhary JS, Almouzni G, Soria JC, Deutsch E, Downs JA, Lord CJ, Postel-Vinay S. Chabanon RM, et al. Among authors: morel d. Cancer Res. 2021 Jun 1;81(11):2888-2902. doi: 10.1158/0008-5472.CAN-21-0628. Cancer Res. 2021. PMID: 33888468
Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results.
Levy A, Morel D, Texier M, Rodriguez-Ruiz ME, Bouarroudj L, Bouquet F, Bustillos A, Quevrin C, Clémenson C, Mondini M, Meziani L, Sun R, Zaghdoud N, Tselikas L, Assi T, Faron M, Honoré C, Ngo C, Verret B, Le Péchoux C, Le Cesne A, Ginhoux F, Massard C, Bahleda R, Deutsch E. Levy A, et al. Among authors: morel d. Signal Transduct Target Ther. 2025 Mar 17;10(1):103. doi: 10.1038/s41392-025-02173-3. Signal Transduct Target Ther. 2025. PMID: 40097400 Free PMC article. Clinical Trial.
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Rodriguez-Ruiz ME, Racadot S, Supiot S, Magné N, Cyrille S, Louvel G, Massard C, Verlingue L, Bouquet F, Bustillos A, Bouarroudj L, Quevrin C, Clémenson C, Mondini M, Meziani L, Tselikas L, Bahleda R, Hollebecque A, Deutsch E. Levy A, et al. Among authors: morel d. Mol Cancer. 2024 Mar 23;23(1):61. doi: 10.1186/s12943-024-01970-8. Mol Cancer. 2024. PMID: 38519913 Free PMC article. Clinical Trial.
Radio-induced lymphopenia in the era of anti-cancer immunotherapy.
de Kermenguy F, Meziani L, Mondini M, Clémenson C, Morel D, Deutsch E, Robert C. de Kermenguy F, et al. Among authors: morel d. Int Rev Cell Mol Biol. 2023;378:1-30. doi: 10.1016/bs.ircmb.2023.03.002. Epub 2023 Apr 3. Int Rev Cell Mol Biol. 2023. PMID: 37438014 Review.
Theragnostic Gadolinium-Based Nanoparticles Safely Augment X-ray Radiation Effects in Patients with Cervical Cancer.
Chargari C, Maury P, Texier M, Genestie C, Morice P, Bockel S, Gouy S, Ba M, Achkar S, Lux F, Tillement O, Dufort S, Duc GLE, Debeaumont O, Massard C, Maulard A, Porcel E, Bahleda R, Ammari S, Morel D, Espenel S, Pautier P, Robert C, Deutsch E. Chargari C, et al. Among authors: morel d. ACS Nano. 2024 Jul 2;18(26):16516-16529. doi: 10.1021/acsnano.3c12537. Epub 2024 Jun 24. ACS Nano. 2024. PMID: 38912600 Clinical Trial.
Low-dose radiotherapy enhances the efficacy of PD-L1 blockade and induces the abscopal effect.
Laurent PA, Shi L, Bouarroudj L, Benzazon N, Gerbé De Thoré M, Liu W, Aglave M, Bergeron P, Naulin F, Sitterlé L, Morel D, Levy A, Clémenson C, Mondini M, Robert C, Meziani L, Deutsch E. Laurent PA, et al. Among authors: morel d. J Immunother Cancer. 2025 Jun 30;13(6):e011487. doi: 10.1136/jitc-2025-011487. J Immunother Cancer. 2025. PMID: 40588370 Free PMC article.
388 results